Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(94 produtos)
- CDK(500 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(42 produtos)
- DYRK(48 produtos)
- Dinamina(23 produtos)
- Ferroptose(215 produtos)
- HSP(169 produtos)
- Integrinas(224 produtos)
- Cinesina(66 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(261 produtos)
- PKC(102 produtos)
- PLK(28 produtos)
- ROCK(70 produtos)
- Rho(2 produtos)
- Wee1(15 produtos)
- c-Myc(69 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3477 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sovesudil hydrochloride
<p>Sovesudil (PHP-201) HCl: potent local ROCK inhibitor; targets ROCK I/II (IC50: 3.7/2.3 nM); lowers IOP, non-congesting.</p>Fórmula:C23H23ClFN3O3Cor e Forma:SolidPeso molecular:443.9CDK12/13 ligand 1
CAS:<p>ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.</p>Fórmula:C26H26BrN5OCor e Forma:SolidPeso molecular:504.42Dyrk1A/B-IN-1
<p>Dyrk1A/B-IN-1 (3n) is a potent DYRK1A/B inhibitor, cell-permeable, with Ki values of 67.8 nM (1A) and 237.9 nM (1B), IC50s of 1.1 and 0.8 μM.</p>Fórmula:C21H17N3O2S2Cor e Forma:SolidPeso molecular:407.51Polθ-IN-6
CAS:<p>Polθ-IN-6 (Compound 89) is an inhibitor of DNA polymerase theta (Polθ) and exhibits antitumor activity.</p>Fórmula:C25H23N3O3SCor e Forma:SolidPeso molecular:445.53BRD-7880
CAS:<p>BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C.</p>Fórmula:C32H38N4O7Cor e Forma:SolidPeso molecular:590.67WRN inhibitor 12
CAS:<p>WRN inhibitor 12 (compound 5) serves as an inhibitor for the WRN helicase.</p>Fórmula:C33H33ClF3N9O5Cor e Forma:SolidPeso molecular:728.12Lobucavir
CAS:<p>Lobucavir (BMS-180194; SQ 34514) is a nucleoside analogue and an antiviral agent with broad-spectrum activity against various viruses, including HBV, HIV/AIDS, and α, β, and γ herpesviruses (including CMV, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus).</p>Fórmula:C11H15N5O3Cor e Forma:SolidPeso molecular:265.27NRTT-IN-1
CAS:<p>NRTT-IN-1 (Compound 1) is an inhibitor of the nucleoside reverse transcriptase translocation (NRTT), effectively blocking HIV DNA synthesis and viral replication.</p>Fórmula:C28H24FN5O5Cor e Forma:SolidPeso molecular:529.519DNA Gyrase-IN-13
CAS:<p>DNA Gyrase-IN-13 (compound 1b) is an inhibitor of DNA gyrase with bacteriostatic properties. It exhibits an IC50 of 1.81 μM against Staphylococcus aureus DNA gyrase.</p>Fórmula:C15H21N3O3SCor e Forma:SolidPeso molecular:323.41RMS-07
CAS:<p>RMS-07, a covalent MPS1/TTK inhibitor, has an IC50 of 13.1 nM, targeting a kinase hinge cysteine.</p>Fórmula:C35H40N8O2Cor e Forma:SolidPeso molecular:604.74D-G23
CAS:<p>D-G23 is a selective RAD52 inhibitor. It disrupts RAD52-mediated DNA repair pathways and suppresses the growth of cancer cells deficient in BRCA1 and BRCA2. D-G23 shows promise for research into homologous recombination-related cancers caused by BRCA1/2 mutations, such as hereditary breast and ovarian cancers.</p>Fórmula:C19H22N4O3Cor e Forma:SolidPeso molecular:354.403P162-0948
CAS:<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Fórmula:C20H15FN4O2Cor e Forma:SolidPeso molecular:362.357GSK3335103
CAS:<p>GSK3335103 is a non-peptide, orally active inhibitor of αvβ6 integrin (pIC50=8), employed in the study of pulmonary fibrosis.</p>Fórmula:C27H36FN3O4Cor e Forma:SolidPeso molecular:485.59Dyrk1A-IN-12
CAS:<p>Dyrk1A-IN-12 (compound S43) is an inhibitor of dual specificity tyrosine phosphorylation regulated kinase 1A (Dyrk1A). It has an IC50 of 95 nM for inhibiting Dyrk1A. The compound demonstrates antiviral activity against EV-A71 (Enterovirus A71) with an EC50 of 4.4 μM, a CC50 of 12.8 μM, and a selectivity index (SI) of 2.9. Additionally, Dyrk1A-IN-12 exhibits potent inhibitory effects on the herpes simplex virus (HSV).</p>Fórmula:C22H16FN3O2SCor e Forma:SolidPeso molecular:405.4455-Iminodaunorubicin hydrochloride
CAS:<p>5-Iminodaunorubicin HCl: quinone-modified anthracycline with antitumor properties, induces DNA breaks in cancer cells.</p>Fórmula:C27H31ClN2O9Cor e Forma:SolidPeso molecular:563.00CDK2 degrader 4
CAS:<p>CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.</p>Fórmula:C23H26ClN3O5Cor e Forma:SolidPeso molecular:459.923LZ9
CAS:<p>LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.</p>Fórmula:C17H11F3N4O2Cor e Forma:SolidPeso molecular:360.29MtTMPK-IN-7
<p>MtTMPK-IN-7 inhibits MtbTMPK (IC50: 47 μM), active against M. brevis (MIC: 2.3-4.7 μM), useful for tuberculosis research.</p>Fórmula:C27H29ClN6O3Cor e Forma:SolidPeso molecular:521.01Rhodblock 1a
CAS:<p>Rhodblock 1a is an inhibitor of the Rho kinase signaling pathway, which disrupts the localization and function of proteins within the Rho pathway. This interference hinders the proper formation of the cleavage furrow during cell division, leading to some cells either failing to form the cleavage furrow or forming a ruptured furrow, resulting in binucleated cells. Rhodblock 1a can be utilized for investigating cell division mechanisms and holds potential for research into cardiovascular diseases and cancer.</p>Fórmula:C20H16N2O2Cor e Forma:SolidPeso molecular:316.353CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Fórmula:C18H20F3N7O3S2Cor e Forma:SolidPeso molecular:503.52Kolavenic acid analog
CAS:<p>KAA, an anticancer compound, inhibits centrosome clustering and targets HSET+ yeast and cancer cells.</p>Fórmula:C25H38O4Cor e Forma:SolidPeso molecular:402.57Zalunfiban dihydrochloride
<p>Zalunfiban (RUC-4) is a potent αIIbβ3 platelet antagonist, IC50 45 nM, used in myocardial infarction research.</p>Fórmula:C16H20Cl2N8O2SCor e Forma:SolidPeso molecular:459.35MtTMPK-IN-9
<p>MtTMPK-IN-9 moderately inhibits MtbTMPK (IC50: 48 μM), has submicromolar Mycobacterium activity, and is non-toxic, aiding tuberculosis research.</p>Fórmula:C25H26N6O7Cor e Forma:SolidPeso molecular:522.51(R)-CSN5i-3
CAS:<p>(R)-CSN5i-3 is CSN5i-3 of the R configuration.</p>Fórmula:C28H29F2N5O2Pureza:99.76% - 99.97%Cor e Forma:SolidPeso molecular:505.56WRN inhibitor 11
CAS:<p>WRN inhibitor 11 (Example 17) is an orally effective inhibitor of WRN helicase, with an IC50 of 63 nM.</p>Fórmula:C34H35ClF3N9O5Cor e Forma:SolidPeso molecular:742.15LY 254155
CAS:<p>LY 254155, an antifolate,binds to mFBP and inhibits hGARFT with Kis of 1.7±0.1 and 2.1±0.2 nM, respectively.</p>Fórmula:C19H23N5O6SPureza:98%Cor e Forma:SolidPeso molecular:449.48LNA-GTP
CAS:<p>LNA-GTP is a nucleotide analog used in the synthesis of oligonucleotides.</p>Fórmula:C11H16N5O14P3Cor e Forma:SolidPeso molecular:535.194,5'-Dimethylangelicin-NHS
<p>NHS-modified coumarin, 4,5'-Dimethylangelicin-NHS, shows photochemical activity & photosensitivity.</p>Fórmula:C21H19NO7SCor e Forma:SolidPeso molecular:429.44DYRKs-IN-1 hydrochloride
CAS:<p>DYRKs-IN-1 HCl inhibits DYRK1A (5 nM IC50) & DYRK1B (8 nM IC50) with antitumor properties.</p>Fórmula:C30H31Cl2N7O4Cor e Forma:SolidPeso molecular:624.52DNA gyrase B-IN-1
<p>DNA gyrase B-IN-1, a potent inhibitor of P. aeruginosa DNA gyrase B, has IC50 of 2.2 μM with high affinity and stability.</p>Fórmula:C23H18ClF3N6O4SCor e Forma:SolidPeso molecular:566.94α5β1 integrin agonist-1
CAS:<p>α5β1 integrin agonist-1 is an α5β1 integrin agonist that selectively delivers 5-FU to tumour cells and induces tumour cell death.</p>Fórmula:C24H26FN5O9Cor e Forma:SolidPeso molecular:547.49(R)-Atuveciclib
CAS:<p>Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].</p>Fórmula:C18H18FN5O2SPureza:98%Cor e Forma:SolidPeso molecular:387.43RAD51-IN-7
CAS:<p>RAD51-IN-7 inhibits RAD51 gene, with potential for mitochondrial disorders. (From WO2021164746A1, cmpd 71)</p>Fórmula:C25H31N5O4S2Cor e Forma:SolidPeso molecular:529.67DNA ligase-IN-2
CAS:<p>DNA ligase-IN-2 (compound 2) acts as a potent LigA inhibitor, effectively hindering the DNA-independent spontaneous adenylation activity of full-length LigA and the truncated enzyme LigA:AD with an IC50 of 29 nM. It also significantly suppresses the in vitro growth of Staphylococcus aureus, showing MIC values of 1 μg/mL for S. aureus ATCC 29213 and S. aureus ATCC 700699, while the MIC for Escherichia coli (E. coli) ATCC 25922 is >64 μg/mL.</p>Fórmula:C13H8FN3O3Cor e Forma:SolidPeso molecular:273.219AR-13324 M1 metabolite
CAS:<p>AR-13324 M1 metabolite is a hydrolysis metabolite of AR-13324 mesylate.</p>Fórmula:C19H19N3O2Pureza:98%Cor e Forma:SolidPeso molecular:321.37Methyl 3-oxodecanoate
CAS:<p>Methyl 3-oxodecanoate exhibits virulence factor activity against human pathogens and shows effects on Synechococcus elongatus (a species of fluorescent algae) as well as on culture supernatant. Additionally, Methyl 3-oxodecanoate inhibits DNA synthesis by suppressing protein synthesis at the translation initiation level.</p>Fórmula:C11H20O3Cor e Forma:SolidPeso molecular:200.275DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49CDK9-IN-13
<p>CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.</p>Fórmula:C27H35N5O2Cor e Forma:SolidPeso molecular:461.62'-O-MOE-GMP
CAS:<p>2'-O-MOE-GMP is a nucleotide analogue that can be utilized in the synthesis of oligonucleotides.</p>Fórmula:C13H20N5O9PCor e Forma:SolidPeso molecular:421.30Chk1-IN-5
CAS:<p>Chk1-IN-5 inhibits Chk1, blocking phosphorylation and suppressing colon cancer growth.</p>Fórmula:C18H18FN7O2Cor e Forma:SolidPeso molecular:383.38CDK9-IN-38
CAS:<p>CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.</p>Fórmula:C22H23N5O3SCor e Forma:SolidPeso molecular:437.515CDK6-IN-1
CAS:<p>CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.</p>Fórmula:C30H23N5Cor e Forma:SolidPeso molecular:453.54N-Isobutyryl-2', 3'-acetyl-guanosine
CAS:<p>N-Isobutyryl-2', 3'-acetyl-guanosine is a derivative of guanosine.</p>Fórmula:C18H23N5O8Cor e Forma:SolidPeso molecular:437.404CYP2C19-IN-1
<p>CYP2C19-IN-1: potent CYP2C19 inhibitor, non-genotoxic, non-hepatotoxic, blocks RdRP (Ki: 6.16 μM), useful for ZIKV research.</p>Fórmula:C26H26N2O6SCor e Forma:SolidPeso molecular:494.56CDK7-IN-31
CAS:<p>CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.</p>Fórmula:C27H32F5N6O2PCor e Forma:SolidPeso molecular:598.55T-2513 hydrochloride
CAS:<p>T-2513 hydrochloride: selective topoisomerase I inhibitor, binds DNA complex, halts DNA/RNA synthesis, causes cell death.</p>Fórmula:C25H28ClN3O5Cor e Forma:SolidPeso molecular:485.96CHK-IN-1
CAS:<p>CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity.</p>Fórmula:C18H19ClFN5OSPureza:>99.99%Cor e Forma:SolidPeso molecular:407.89Hesperadin hydrochloride
<p>Hesperadin hydrochloride is an ATP-competitive indolone inhibitor of Aurora A and B, with an IC50 value of 250 nM for Aurora B.</p>Fórmula:C29H33ClN4O3SCor e Forma:SolidPeso molecular:553.12LNA-AMP
CAS:<p>LNA-AMP is a nucleotide analog used in the synthesis of oligonucleotides.</p>Fórmula:C11H14N5O7PCor e Forma:SolidPeso molecular:359.23CDK1-IN-7
CAS:<p>CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.</p>Fórmula:C23H19ClN4O3Cor e Forma:SolidPeso molecular:434.88CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Cor e Forma:SolidDyrk1A-IN-2
<p>Dyrk1A-IN-2 is a DYRK1A inhibitor (EC50: 37 nM). dyrk1A-IN-2 exhibits efficient promotion of human β-cell replication, as well as low cytotoxicity.</p>Fórmula:C27H32N6O4Cor e Forma:SolidPeso molecular:504.58Dmf-dg
CAS:<p>Dmf-dg (2'-Deoxy-N2-dimethylaminomethylene-guanosine) is a nucleoside of deoxyguanosine (dG) with a dimethylaminomethylene (DMF) base protection, employed in the synthesis of oligonucleotides.</p>Fórmula:C13H18N6O4Cor e Forma:SolidPeso molecular:322.32UMPK ligand 1
CAS:<p>UMPK ligand 1 (ZINC07785412) serves as a ligand for uridine monophosphate kinase (UMPK).</p>Fórmula:C15H22N4O5SCor e Forma:SolidPeso molecular:370.4242'-F-CDP
CAS:<p>2'-F-CDP is a nucleotide analog that can be utilized in the synthesis of oligonucleotides.</p>Fórmula:C9H14FN3O10P2Cor e Forma:SolidPeso molecular:405.17β-catenin-IN-8
CAS:<p>β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.</p>Fórmula:C15H12ClN3O2SCor e Forma:SolidPeso molecular:333.79PLK1-IN-5
CAS:<p>PLK1-IN-5, a potent PLK1 inhibitor, has an IC50 of less than 500 nM and demonstrates anticancer effects (WO2008113711A1; compound I-4) [1].</p>Fórmula:C28H39N7O3Cor e Forma:SolidPeso molecular:521.65(Rac)-Plevitrexed
CAS:<p>(Rac)-Plevitrexed is a racemate of Plevitrexed. Plevitrexed is an orally active and potent inhibitor of thymidylate synthase (TS).</p>Fórmula:C26H25FN8O4Pureza:98%Cor e Forma:SolidPeso molecular:532.53INX-315
CAS:<p>INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.</p>Fórmula:C19H21N7O3SPureza:99.88%Cor e Forma:SolidPeso molecular:427.48Dyrk1A-IN-8
CAS:<p>Dyrk1A-IN-8 is an active molecule that can be used in life science related research. The CAS number of Dyrk1A-IN-8 is 101578-13-6.</p>Fórmula:C17H21N3OCor e Forma:SolidPeso molecular:283.37CHK1-IN-11
CAS:<p>CHK1-IN-11 (Compound 1) is an orally active inhibitor of checkpoint kinase 1 (CHK1). It is utilized in research focused on cancers with oncogene amplification.</p>Fórmula:C20H22N8O2Cor e Forma:SolidPeso molecular:406.44CDK2 degrader 6
CAS:<p>CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.</p>Fórmula:C23H22F5N5O3Cor e Forma:SolidPeso molecular:511.44LNA-CTP
CAS:<p>LNA-CTP is a nucleotide analog utilized in the synthesis of oligonucleotides.</p>Fórmula:C10H16N3O14P3Cor e Forma:SolidPeso molecular:495.17RNAP-σ interaction inhibitor-2
CAS:<p>RNAP-σ interaction inhibitor-2 (compound 7d) is an inhibitor targeting the interaction between RNA polymerase and the sigma factor. It demonstrates inhibitory activity against S. aureus with a minimum inhibitory concentration (MIC) of 2 µg/mL.</p>Fórmula:C27H19Cl3N2O6S2Cor e Forma:SolidPeso molecular:637.939Antiviral agent 67
CAS:<p>Antiviralagent 67 (compound PC6) is an inhibitor of DENVNS5 (RNA-dependent RNA polymerase) with a Ki value of 1.12 nM.</p>Fórmula:C19H19N3OCor e Forma:SolidPeso molecular:305.374CD 10899
CAS:<p>CD 10899, a hydroxylated metabolite of Volasertib, is pharmacologically active against Polo-like kinase 1 (PLK1) with an IC50 of 6 nM. Volasertib is an orally active, highly potent, and ATP-competitive PLK1 inhibitor. CD 10899 can be used for cancer research [1].</p>Fórmula:C34H50N8O4Cor e Forma:SolidPeso molecular:634.81iPAF1C
CAS:<p>iPAF1C is a powerful inhibitor of the polymerase-associated factor 1 complex (PAF1C) and exhibits anti-HIV activity [1].</p>Fórmula:C27H26BrFN4OCor e Forma:SolidPeso molecular:521.42CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Fórmula:C21H22N4OCor e Forma:SolidPeso molecular:346.432,5-Di-tert-butyl-1,4-benzoquinone
CAS:<p>2,5-Di-tert-butyl-1,4-benzoquinone is a potent antibacterial agent found primarily in marine Streptomyces sp. VITVSK1, effective against emerging antibiotic resistance. Additionally, it serves as a powerful inhibitor of RNA polymerase.</p>Fórmula:C14H20O2Cor e Forma:SolidPeso molecular:220.31Mps1-IN-8
CAS:<p>Mps1-IN-8, a Mps1 inhibitor, can be utilized in the study of various tumors [1].</p>Fórmula:C35H47N8O6PCor e Forma:SolidPeso molecular:706.77WRN inhibitor 7
CAS:<p>WRN inhibitor 7 (Compound h6), a potent inhibitor of Werner syndrome helicase, demonstrates effective suppression of WRN's helicase and ATPase activities with IC50 values of 9.8 μM and 15.8 μM, respectively. This compound is utilized in the study of microsatellite instable (MSI) cancers [1].</p>Fórmula:C27H23N3O6Cor e Forma:SolidPeso molecular:485.49N-Nitrosonornicotine
CAS:<p>N-Nitrosonornicotine, a tobacco-specific nitrosamine, exhibits carcinogenic and mutagenic properties, and is capable of inducing micronuclei in C3A cells. Additionally, N-Nitrosonornicotine can form DNA adducts.</p>Fórmula:C9H11N3OCor e Forma:SolidPeso molecular:177.2DB18
CAS:<p>DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].</p>Fórmula:C24H18ClN7O3Cor e Forma:SolidPeso molecular:487.9VPC-80051
CAS:<p>VPC-80051 is an hnRNP A1 splicing activity inhibitor that directly interacts with the hnRNP A1 RBD and reduces AR-V7 messenger levels in the 22Rv1 CRPC cell line. VPC-80051 is applicable in prostate cancer research.</p>Fórmula:C16H13F2N3OCor e Forma:SolidPeso molecular:301.291LIMK-IN-2
CAS:<p>LIMK-IN-2 (Compound 52), an LIMK inhibitor, has demonstrated potential anti-angiogenic activity by suppressing the cell migration of osteosarcoma and cervical cancer cells [1].</p>Fórmula:C28H27N5O2Cor e Forma:SolidPeso molecular:465.555'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine
CAS:<p>5'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine is a nucleoside synthesized through oxime ring-opening at the 5' position and methylation at the 2' position. In chemotaxis assays, 5'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine demonstrates tissue affinity.</p>Fórmula:C36H39N5O8Cor e Forma:SolidPeso molecular:669.724TMX-3013
CAS:<p>TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.</p>Fórmula:C17H14BrFN6O3SCor e Forma:SolidPeso molecular:481.3PKMYT1-IN-2
CAS:<p>PKMYT1-IN-2 (compound 2) serves as a powerful inhibitor of PKMYT1, exhibiting an IC 50 of 5.7 nM. Additionally, it effectively suppresses the proliferation of HCC1569 cells with an IC 50 of 22 nM [1].</p>Fórmula:C22H19N5O2Cor e Forma:SolidPeso molecular:385.42PLK1-IN-11
CAS:<p>PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor with an IC50 of 1 μM. It is applicable in research on various cancers such as pancreatic, ovarian, breast, and non-small cell lung cancer.</p>Fórmula:C12H11N5OCor e Forma:SolidPeso molecular:241.2492'-O-MOE-GTP
CAS:<p>2'-O-MOE-GTP is a nucleotide analog utilized in the synthesis of oligonucleotides.</p>Fórmula:C13H22N5O15P3Cor e Forma:SolidPeso molecular:581.26PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Fórmula:C17H18FN5O3Cor e Forma:SolidPeso molecular:359.355PolQi1
CAS:<p>PolQi1 is a highly efficient and selective Polϴ (DNA polymerase theta) inhibitor with an IC50 of 2 nM, showing potential for cancer therapy.</p>Fórmula:C18H14ClF5N4O2Pureza:98.97%Cor e Forma:SolidPeso molecular:448.77NusB-IN-1
<p>NusB-IN-1 (22r) is an oral bacterial rRNA inhibitor, effective against MRSA and VRSA.</p>Fórmula:C21H16N2O3Cor e Forma:SolidPeso molecular:344.36ROCK-IN-11
CAS:<p>ROCK-IN-11 (example 94) is an effective inhibitor of ROCK1 and ROCK2, with an IC50 of ≤ 5 μM, and plays a significant role in cancer research.</p>Fórmula:C22H20N4O4SCor e Forma:SolidPeso molecular:436.484WEE1-IN-11
CAS:<p>WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.</p>Fórmula:C26H29FN8OS2Cor e Forma:SolidPeso molecular:552.69PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Fórmula:C25H27N7Cor e Forma:SolidPeso molecular:425.53WEE1 degrader 1
<p>WEE1degrader 1 (Compound 10) functions as a Wee1 degrader, exhibiting a DC50 value of 1.5 nM against Wee1. This compound also possesses anticancer properties that inhibit cell proliferation.</p>Fórmula:C30H31N5O3Cor e Forma:SolidPeso molecular:509.6CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Fórmula:C21H23N7O2SCor e Forma:SolidPeso molecular:437.52Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28Uridine 3',5'-diphosphate
CAS:<p>Uridine 3′,5′-diphosphate (3′,5′-UDP; Compound pUp) serves as a competitive RNase inhibitor [1].</p>Fórmula:C9H14N2O12P2Cor e Forma:SolidPeso molecular:404.16Dyrk1A-IN-4
CAS:<p>Dyrk1A-IN-4, compound 48, is an oral DYRK1A/DYRK2 inhibitor with IC50s: 2 nM (DYRK1A), 6 nM (DYRK2), anticancer properties.</p>Fórmula:C14H13F3N6Cor e Forma:SolidPeso molecular:322.29DHX9-IN-9
CAS:<p>DHX9-IN-9 (509) acts as an inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 0.0177 μM in DHX9 cellular target engagement, primarily utilized in cancer research [1].</p>Fórmula:C21H21ClFN5O3S2Cor e Forma:SolidPeso molecular:510Plevitrexed
CAS:<p>Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.</p>Fórmula:C26H25FN8O4Pureza:98%Cor e Forma:SolidPeso molecular:532.532′-O-MOE-CMP
CAS:<p>2′-O-MOE-CMP is a nucleotide analogue utilized in the synthesis of oligonucleotides.</p>Fórmula:C12H20N3O9PCor e Forma:SolidPeso molecular:381.28RAD51-IN-8
<p>RAD51-IN-8 inhibits RAD51-BRCA2 interaction and H4A4 with EC50 of 19 μM; a micromolar PPI inhibitor.</p>Fórmula:C16H14Cl2FN3O2Cor e Forma:SolidPeso molecular:370.21CIB-L43
CAS:<p>CIB-L43 is a oral TRBP inhibitor, inhibit miR-21, increase PTEN and Smad7, and block the AKT and TGF-β，inhibit proliferation and migration.</p>Fórmula:C15H16N2O3SPureza:99.64%Cor e Forma:SolidPeso molecular:304.36Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47Polθ-IN-8
CAS:<p>Polθ-IN-8 (example 77) is a DNA polymerase θ (Polθ) inhibitor with an IC50 for Polθ ATPase activity of less than 100 nM. Polθ-IN-8 is useful for researching diseases related to Polθ activity, such as cancer.</p>Fórmula:C22H22ClN7O3SCor e Forma:SolidPeso molecular:499.97Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Fórmula:C18H13N3O2Cor e Forma:SolidPeso molecular:303.31
